OBJECTIVE: Frontotemporal dementia (FTD) is a common cause of young onset dementia. Very few reports on disease duration are currently available and predictors of survival are still undefined. The aim of the present study was to assess the natural history of FTD and to define predictors of survival. METHODS: Four hundred amd eleven FTD patients, including 294 with behavioural variant FTD, 77 with agrammatic variant primary progressive aphasia (PPA) and 40 with semantic variant PPA, were consecutively enrolled and demographic and clinical variables carefully recorded. Each patient underwent genetic screening for monogenic disease. RESULTS: The mean survival time from onset of the symptoms was 7.8 ± 4.0 years. The presence o...
Objective: Only a few studies have evaluated modifiable risk factors for frontotemporal dementia (FT...
Background and Objectives Disease-modifying therapeutic trials for genetic frontotemporal dementia (...
Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in pres...
BACKGROUND: Behavioral variant frontotemporal dementia (bvFTD) is a common cause of younger onset de...
Background: Behavioral variant frontotemporal dementia (bvFTD) is generally considered a young-onset...
BACKGROUND: Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third...
BACKGROUND: Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third...
Abstract—Objective: To compare survival and rates of cognitive and functional decline in patients wi...
BACKGROUND: Frontotemporal dementia and amyotrophic lateral sclerosis are neurodegenerative diseases...
Objective: In this prospective cohort study, we performed a 2-year follow-up study with neuropsychol...
OBJECTIVES: Chromosome 3-linked frontotemporal dementia (FTD-3) is caused by a c.532-1G > C mutation...
We investigated the survival time of each clinical syndrome of frontotemporal dementia (FTD) and the...
Objective To assess the clinical course and prognosis in patients with behavioral-variant frontotem...
Introduction: We performed 4-year follow-up neuropsychological assessment to investigate cognitive d...
Objectives: The aim of this study was to investigate survival time and life-expectancy in people wit...
Objective: Only a few studies have evaluated modifiable risk factors for frontotemporal dementia (FT...
Background and Objectives Disease-modifying therapeutic trials for genetic frontotemporal dementia (...
Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in pres...
BACKGROUND: Behavioral variant frontotemporal dementia (bvFTD) is a common cause of younger onset de...
Background: Behavioral variant frontotemporal dementia (bvFTD) is generally considered a young-onset...
BACKGROUND: Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third...
BACKGROUND: Frontotemporal dementia is a heterogenous neurodegenerative disorder, with about a third...
Abstract—Objective: To compare survival and rates of cognitive and functional decline in patients wi...
BACKGROUND: Frontotemporal dementia and amyotrophic lateral sclerosis are neurodegenerative diseases...
Objective: In this prospective cohort study, we performed a 2-year follow-up study with neuropsychol...
OBJECTIVES: Chromosome 3-linked frontotemporal dementia (FTD-3) is caused by a c.532-1G > C mutation...
We investigated the survival time of each clinical syndrome of frontotemporal dementia (FTD) and the...
Objective To assess the clinical course and prognosis in patients with behavioral-variant frontotem...
Introduction: We performed 4-year follow-up neuropsychological assessment to investigate cognitive d...
Objectives: The aim of this study was to investigate survival time and life-expectancy in people wit...
Objective: Only a few studies have evaluated modifiable risk factors for frontotemporal dementia (FT...
Background and Objectives Disease-modifying therapeutic trials for genetic frontotemporal dementia (...
Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in pres...